Peer Enhanced Prolonged Exposure (PEET)
Peer Enhanced Exposure Therapy (PEET)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417
- Minneapolis VA Health Care System, Minneapolis, MN
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Veteran participants will be individuals appropriate for PE, i.e., :
- Veterans who are currently seeking PE
- meet DSM-5 criteria for PTSD or subthreshold PTSD
- are competent to consent to research
Exclusion Criteria:
- Veteran participants do not have levels of other types of psychopathology that would prevent successful participation in the intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PEET
Peer support interventions as an adjunct to prolonged exposure
|
Peer support interventions as adjunct to prolonged exposure
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PE Sessions Attended
Time Frame: 10 weeks
|
Number of PE Sessions attended during 10 weeks of participation in study.
10 is the maximum, 0 is the minimum.
Higher numbers of sessions attended are an indication of better engagement in treatment.
|
10 weeks
|
|
Posttraumatic Stress Disorder (PTSD) Checklist-5
Time Frame: 10 weeks
|
Self-report measure of PTSD symptoms; score range is 0-80, with higher scores indicating more PTSD symptoms.
|
10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jeanette I. Harris, PhD, Minneapolis VA Health Care System, Minneapolis, MN
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- D2188-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.